This immunosuppressive TME poses challenges for effective cancer therapies, including the use of chimeric antigen receptor (CAR) T cells to significantly inhibit tumor growth and improve survival by targeting tumor-associated antigens like EpCAM, EGFR, and ROR1 [49,50]. Here, ROR1 is linked to neoplasm.